Assay method for Alzheimer's disease
US9453069B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 16, 2013 |
| Grant date | Sep 27, 2016 |
| Priority date | — |
| Expiry date | Apr 16, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2821
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of Aβ40, Aβ42, their ratio, or their rate of entry following administration of antibodies that sequester Aβ. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.